US 7504430
Maleiimide anti-tumor phosphatase inhibitors
granted A61PA61P35/00
Quick answer
US patent 7504430 (Maleiimide anti-tumor phosphatase inhibitors) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Mar 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 41
- CPC classes
- A61P, A61P35/00